CoChat

Are pvcrt-o and pvmdr1 Gene Mutations Associated with Plasmodium vivax Chloroquine-Resistant Parasites?

Open access
Abreu-Fernandes, Rebecca de, Almeida-de-Oliveira, Natália Ketrin, de Lavigne Mello, Aline Rosa, Queiroz, Lucas Tavares de, Barros, Jacqueline de Aguiar, Baptista, Bárbara de Oliveira, Oliveira-Ferreira, Joseli, Souza, Rodrigo Medeiros de, Pratt-Riccio, Lilian Rose, Brasil, Patrícia, Daniel-Ribeiro, Cláudio Tadeu, Ferreira-da-Cruz, Maria de Fátima · 2024 · Biomedicines

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; none of the 31 sources its claims cite is checked for support yet.

Abstract

(1) Background: Malaria remains a significant global public health issue. Since parasites quickly became resistant to most of the available antimalarial drugs, treatment effectiveness must be constantly monitored. In Brazil, up to 10% of cases of vivax malaria resistant to chloroquine (CQ) have been registered. Unlike P. falciparum, there are no definitive molecular markers for the chemoresistance of P. vivax to CQ. This work aimed to investigate whether polymorphisms in the pvcrt-o and pvmdr1 genes could be used as markers for assessing its resistance to CQ. (2) Methods: A total of 130 samples from P. vivax malaria cases with no clinical and/or parasitological evidence of CQ resistance were studied through polymerase chain reaction for gene amplification followed by target DNA sequencing. (3) Results: In the pvcrt-o exons, the K10 insert was present in 14% of the isolates. Regarding pvmdr1, T958M and F1076L haplotypes showed frequencies of 95% and 3%, respectively, while the SNP Y976F was not detected. (4) Conclusions: Since K10-pvcrt-o and F1076L/T958M-pvmdr1 polymorphisms were detected in samples from patients who responded well to CQ treatment, it can be concluded that mutations in these genes do not seem to have a potential for association with the phenotype of CQ resistance.

Overview

CoChat Summary

TL;DR

In 130 *Plasmodium vivax* samples from Brazilian Amazon areas, with no clinical or parasitological evidence of chloroquine resistance, the *pvcrt-o* K10 insertion and *pvmdr1* T958M/F1076L polymorphisms were detected but *pvmdr1* Y976F was absent. Because carriers responded well to chloroquine treatment, the authors conclude these mutations do not appear to be promising markers of *P. vivax* chloroquine resistance.

Key findings

  • For *pvcrt-o*, 104/130 (80%) samples were sequenced; the K10 insertion was detected in 15 (14%) samples, while 89 (86%) had no mutations and matched the Sal-1 wild-type reference.
  • For *pvmdr1*, 113/130 (86%) samples were sequenced; T958M was the most prevalent SNP (93%) and was found in all states, F1076L was present in only three Amazonas samples (12% of n = 25), and Y976F was absent in all samples.
  • Haplotype analysis showed the MYF single-mutant profile in 104/113 (92%) samples; the MYL double-mutant profile (T958M + F1076L) was detected exclusively in 12% (3/25) of Amazonas samples, and F1076L was always associated with T958M.
  • Patients carrying K10-*pvcrt-o* parasites from the endemic area had no recrudescence until 60 days after treatment, and the three patients with double-mutant MYL *pvmdr1* parasites were cured within the expected time.

Methods

  • A total of 130 *P. vivax* malaria cases with no clinical and/or parasitological evidence of chloroquine resistance were studied; samples were collected from January 2018 to August 2022 in six Amazonian states (Acre, Amazonas, Amapá, Pará, Rondônia, and Roraima).
  • Malaria diagnosis used light microscopy and PCR, with species-specific PCR to confirm *P. vivax* mono-infection; patients received chloroquine for 3 days plus primaquine for 7 days and were followed on days 0, 1, 2, 3, 7, 14, 28, and 42.
  • DNA was extracted, PCR-amplified for ~1186 bp of *pvcrt-o* and 800 bp of *pvmdr1*, sequenced, aligned against Sal-1 reference sequences, and analyzed for SNPs and haplotypes.

Limitations

  • Paper-stated: mechanisms of *P. vivax* resistance remain unclear due to the lack of continuous in vitro culture and possible multigenic loci; the authors could not draw conclusions about Y976F because it was absent, and they note the small possibility of primaquine acting against minority chloroquine-resistant parasite clones.
  • Evident from the text: only samples without clinical or parasitological evidence of chloroquine resistance were included, so the study cannot directly compare resistant and sensitive phenotypes; sequencing was incomplete (104/130 for *pvcrt-o*, 113/130 for *pvmdr1*), and some state sample sizes were very small (Pará n = 1, Rondônia n = 2, Amapá n = 2).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomedicines12010141

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Brazilian map highlighting the Acre (AC), Amazonas (AM), Amapá (AP), Pará (PA), Rondônia (RO) and Roraima (RR) states and the municipalities of parasite infection.
Figure 1 Brazilian map highlighting the Acre (AC), Amazonas (AM), Amapá (AP), Pará (PA), Rondônia (RO) and Roraima (RR) states and the municipalities of parasite infection.CC BY · PubMed Central
Figure 2 Alignment of representative CQ-resistant and -sensitive pvcrt-o sequences, with the K10 insertion highlighted in red. Melo R1 to R12 correspond to CQ-resistant sequences of Melo et al. [20]. The sequences named K10 01 to 31 correspond to the isolates sequenced in this study. AC: Acre; AM: Amazonas; AP: Amapá; PA: Pará; RO: Rondônia; RR: Roraima.
Figure 2 Alignment of representative CQ-resistant and -sensitive pvcrt-o sequences, with the K10 insertion highlighted in red. Melo R1 to R12 correspond to CQ-resistant sequences of Melo et al. [20]. The sequences named K10 01 to 31 correspond to the isolates sequenced in this study. AC: Acre; AM: Amazonas; AP: Amapá; PA: Pará; RO: Rondônia; RR: Roraima.CC BY · PubMed Central
Figure 3 Alignment of representative CQ-resistant and -sensitive pvmdr1 sequences, with the SNPs investigated highlighted in red (T958M, Y976F and F1076L). Melo R1 to R12 correspond to CQ-resistant sequences of Melo et al. [20]. The sequences named TYF correspond to the isolates with the wild-type haplotype sequenced in this study. Sequences named MYL and MYF correspond to the isolates with one and two non-synonymous mutations detected in this study, respectively. AC: Acre; AM: Amazonas; AP: Amapá; PA: Pará; RO: Rondônia; RR: Roraima.
Figure 3 Alignment of representative CQ-resistant and -sensitive pvmdr1 sequences, with the SNPs investigated highlighted in red (T958M, Y976F and F1076L). Melo R1 to R12 correspond to CQ-resistant sequences of Melo et al. [20]. The sequences named TYF correspond to the isolates with the wild-type haplotype sequenced in this study. Sequences named MYL and MYF correspond to the isolates with one and two non-synonymous mutations detected in this study, respectively. AC: Acre; AM: Amazonas; AP: Amapá; PA: Pará; RO: Rondônia; RR: Roraima.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 13 Not checked · 28 Own results and interpretations

22 more claims

Create a free account to see all 41 claims and to verify the 31 references still open.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 10
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 54 references

Cited by

See all 5

Metadata

Authors
Abreu-Fernandes, R. D., Almeida-de-Oliveira, N. K., de Lavigne Mello, A. R., Queiroz, L. T. D., Barros, J. D. A., Baptista, B. D. O., Oliveira-Ferreira, J., Souza, R. M. D., Pratt-Riccio, L. R., Brasil, P., Daniel-Ribeiro, C. T., & Ferreira-da-Cruz, M. D. F.
Affiliations
  • Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21041-361, Brazil
  • Ministério da Saúde (BR)
  • Instituto Oswaldo Cruz (BR)
  • Fundação Oswaldo Cruz (BR)
  • Laboratório de Doenças Infecciosas da Amazônia Ocidental, Universidade Federal do Acre, Campus Floresta, Cruzeiro do Sul 69980-000, Brazil
Venue
Biomedicines
Publisher
MDPI AG
Published
2024-01-09
Volume
12
Issue
1
Pages
141
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4390695860
Cited by
5
References
54
Citations by year
2026: 3 · 2024: 2
FWCI
1.33
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Arca - Repositório Institucional da Fiocruz (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (310445/2017-5, 306025/2018-3, 311562/2021-3, E-26/202.921/2018, E-26/203.295/2015, E-26/200.925/2022, 402675/2018-5, 026-FIO-18-2-1)
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado de Rio de Janeiro (310445/2017-5, 306025/2018-3, 311562/2021-3, E-26/202.921/2018, E-26/203.295/2015, E-26/200.925/2022, 402675/2018-5, 026-FIO-18-2-1)
  • Departamento de Ciência e Tecnologia em Saúde/Ministério da Saúde (DECIT/MS) (310445/2017-5, 306025/2018-3, 311562/2021-3, E-26/202.921/2018, E-26/203.295/2015, E-26/200.925/2022, 402675/2018-5, 026-FIO-18-2-1)
  • Programa Nacional de Controle e Prevenção da Malária/Secretaria de Vigilância em Saúde/Ministério da Saúde (SVS/MS) and Fiocruz (310445/2017-5, 306025/2018-3, 311562/2021-3, E-26/202.921/2018, E-26/203.295/2015, E-26/200.925/2022, 402675/2018-5, 026-FIO-18-2-1)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
Plasmodium vivax, chloroquine resistance, pvcrt-o, pvmdr1, drug resistance markers, vivax malaria, antimalarial drug resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Are pvcrt-o and pvmdr1 Gene Mutations Associated with Plasmodium vivax Chloroquine-Resistant Parasites? https://app.cochat.ai/papers/10.3390/biomedicines12010141
The paper
Abreu-Fernandes, R. D., Almeida-de-Oliveira, N. K., de Lavigne Mello, A. R., Queiroz, L. T. D., Barros, J. D. A., Baptista, B. D. O., Oliveira-Ferreira, J., Souza, R. M. D., Pratt-Riccio, L. R., Brasil, P., Daniel-Ribeiro, C. T., & Ferreira-da-Cruz, M. D. F. (2024). Are pvcrt-o and pvmdr1 Gene Mutations Associated with Plasmodium vivax Chloroquine-Resistant Parasites? Biomedicines. https://doi.org/10.3390/biomedicines12010141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.